They are absolutely frightened by the prospect of a competitor coming in with a cheaper, more consistent and more potent product. Which is exactly what Cynata offers. If I held MSB and objectively read the announcement today, I would be petrified and running for the hills. That announcement conveys a management team that knows they are living on borrowed time.
What they specifically included and excluded from that announcement painted a clear picture of where they see the threat to their business model. That threat is Cynata.
- Forums
- ASX - By Stock
- Why Orphan Drug Designation for mesoblast is IRRELEVANT to Cynata
CYP
cynata therapeutics limited
Add to My Watchlist
2.94%
!
16.5¢

They are absolutely frightened by the prospect of a competitor...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M |
Open | High | Low | Value | Volume |
16.5¢ | 17.0¢ | 16.5¢ | $39.66K | 238.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 277684 | 16.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 14285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 277684 | 0.165 |
6 | 607381 | 0.160 |
3 | 26451 | 0.155 |
3 | 115000 | 0.150 |
2 | 45937 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 14285 | 1 |
0.180 | 108494 | 4 |
0.185 | 94565 | 3 |
0.190 | 133868 | 2 |
0.195 | 19300 | 1 |
Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |